Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.55 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 7/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | NMT2 | O60551 | 1/20 | 0.51 |
| ▸ | NMT1 | P30419 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202817 | 0.94 | NMT2 (0.59) | NOD1PLA2G10GLP1RSIRT6SIRT1 | |
| SCHEMBL22684576 | 0.92 | SIRT6 (0.63) | GLP1RSIRT6SIRT1TLR2LPAR3 | |
| SCHEMBL6931475 | 0.92 | NOD1 (0.60) | NOD1PLA2G2CPLA2G10GLP1RLPAR3 | |
| SCHEMBL9517290 | 0.91 | GLP1R (0.61) | NOD1PLA2G2CGLP1RLPAR3 | |
| SCHEMBL9441752 | 0.91 | GLP1R (0.61) | NOD1PLA2G2CGLP1RLPAR3 | |
| SCHEMBL2339541 | 0.87 | NMT1 (0.63) | NOD1GLP1RSIRT6SIRT1TLR2 | |
| SCHEMBL15720865 | 0.87 | NMT1 (0.63) | NOD1GLP1RSIRT6SIRT1TLR2 | |
| SCHEMBL15720614 | 0.87 | NMT1 (0.63) | NOD1GLP1RSIRT6SIRT1TLR2 | |
| SCHEMBL14683578 | 0.86 | NOD1 (0.52) | NOD1PLA2G2CPLA2G10GLP1RLPAR3 | |
| SCHEMBL15720863 | 0.86 | SIRT6 (0.64) | NOD1GLP1RSIRT6SIRT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | NOD1 3454/4885PLA2G2C 382/4885PLA2G10 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.